SCHEMBL10129758

SCHEMBL10129758

COC(=O)Cc1ccc(-c2c3ccccc3c(-c3ccc(CC(=O)OC)cc3)c3c(N(c4ccccc4)c4ccc(-n5c6ccccc6c6ccccc65)cc4)cccc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
RXRA P19793 2/20 0.36
RXRB P28702 2/20 0.36
PTGER4 P35408 3/20 0.35
PTPN1 P18031 1/20 0.35
HDAC4 P56524 1/20 0.34
AKR1C4 P17516 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
PLA2G2A P14555 1/20 0.33
GPR88 Q9GZN0 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10129307 0.94 HPGD (0.40) HPGDMAPTTSHRRXRARXRB
SCHEMBL10129322 0.90 HPGD (0.38) HPGDMAPTTSHRRXRARXRB
SCHEMBL10112618 0.86 ALDH1A1 (0.41) HPGDMAPTPTGER4HDAC4CYP1A2
SCHEMBL10129760 0.86 HPGD (0.47) HPGDMAPTTSHRRXRARXRB
SCHEMBL10112613 0.83 RORC (0.43) MAPTPTGER4PTPN1HDAC4CYP1A2
SCHEMBL10112628 0.83 EDNRA (0.39) HPGDMAPTTSHRCYP1A2CYP2D6
SCHEMBL10129313 0.83 HPGD (0.46) HPGDMAPTTSHRRXRARXRB
SCHEMBL8406187 0.82 L3MBTL1 (0.41) MAPTHDAC4RORCKDM4EALDH1A1
SCHEMBL8406178 0.82 L3MBTL1 (0.42) MAPTPTPN1HDAC4RORCKDM4E
SCHEMBL13209233 0.81 KDM4E (0.38) MAPTHDAC4AKR1C4AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
EP-1918350-B1 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LAB (JP) 2010-08-11 EP disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
EP-1918350-A2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-07 EP disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative AMY1A, CYP1A1, CRY1 HPGD 372/4885MAPT 4092/4885TSHR 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.